PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007
REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:
ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2
May 2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from Aviva plc and
Aviva Investors Global Services Limited.

The above shareholders notified that they have exceeded the 3% threshold and
now hold 1,482,342 Ablynx shares, which represent 3.04% of the current
48,827,646 outstanding shares of Ablynx.

The voting rights are managed and controlled by Aviva Investors Global
Services Limited, with the following chain of controlled undertakings: Aviva
plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary of
Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva
Group Holdings Limited), Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency notifications are available on the website
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and seven Nanobodies at
clinical development stage. Ablynx has on-going research collaborations and
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The
Company is headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.

press release in pdf format: http://hugin.info/137912/R/1739362/583729.pdf

CONTACT: Ablynx:
         Dr Edwin Moses
         Chairman and CEO
         t: +32 (0)9 262 00 07
         m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
         e: edwin.moses@ablynx.com
        
         Marieke Vermeersch
         Associate Director Investor Relations
         t: +32 (0)9 262 00 82
         m: +32 (0)479 49 06 03
         e: marieke.vermeersch@ablynx.com
         Follow us on Twitter @AblynxABLX
        
         Ablynx media relations Consilium Strategic Communications:
         Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
         t: +44 207 920 2345
         e: ablynx@consilium-comms.com